(Polmacoxib + tramadol) is under clinical development by CrystalGenomics and currently in Phase I for Osteoarthritis. According to GlobalData, Phase I drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Polmacoxib + tramadol) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Polmacoxib + tramadol) overview
CG-650 is a fixed dose combination of polmacoxib and tramadol is under development for the treatment of acute and chronic pain, osteoarthritis. It is administered orally. Polmacoxib acts by targeting cyclooxygenase 2 (COX-2) and carbonic anhydrase whereas tramadol acts by targeting mu-opioid receptor, noradrenaline transporter (NAT) and serotonin transporter (SERT).
CrystalGenomics is a biopharmaceutical company that discovers and develops structural chemoproteiomics-based drugs. The company’s pipeline products include CG-650 used for the treatment of acute chronic pain; CG-651, targeting neuropathic pain; CG-598 against inflammatory bowel disease; CG-549 used for the treatment of infectious diseases; CG-745 investigating for the traetment of pancreatic cancer, myelodysplastic syndrome and acute myeloid leukemia; CG-806, against blood cancer and CG-750 for treating fibrosis. CrystalGenomics uses its proprietary technologies to determine the structure of proteins, generate lead compounds; and optimize novel leads to drug candidate compounds. The company also provides soluble, active and homogeneous forms of disease related proteins. CrystalGenomics is headquartered in Seongnam, South Korea.
For a complete picture of (Polmacoxib + tramadol)’s drug-specific PTSR and LoA scores, buy the report here.